Effects of idebenone on monoamine metabolites in cerebrospinal fluid of patients with cerebrovascular dementia.

Kawakami M, Itoh T.

3rd Department of Internal Medicine, 
St. Marianna University School of Medicine
Kawasaki, Japan.
Arch Gerontol Geriatr 1989 May;8(3):343-53


Monoamine metabolites and norepinephrine (NE) in the cerebrospinal fluid of patients with cerebrovascular dementia were measured to study the effects of administration of idebenone. Six patients with cerebral infarction and one with cerebral hemorrhage (mean age 65.4 years) were enrolled as subjects. All the patients had mental and intelligence impairment which was evaluated by the Hasegawa's Dementia Rating (DR) Scale. The patients were medicated with a 90 mg/day dose of idebenone for 1 to 2 months, and homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA), 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) and NE in the cerebrospinal fluid were determined by high-performance liquid chromatography before and after the medication of idebenone. Before the medication, the level of HVA was 21.7 +/- 1.4 ng/ml (mean +/- SE), which was significantly lower (p less than 0.01) as compared with that in control subjects of similar age. The level of 5-HIAA was 18.5 +/- 2.7 ng/ml, and that of MHPG 9.5 +/- 0.7 ng/ml, both of which were lower than those of the controls, though statistically not significant. NE was similar to the control value. After administration of idebenone, HVA measured was 27.1 +/- 3.2 ng/ml, showing a tendency to increase. The levels of 5-HIAA and MHPG were 26.7 +/- 2.3 ng/ml and 10.7 +/- 0.6 ng/ml, respectively, which were significantly (p less than 0.05) higher than the premedication values. The percentages of the change were 12.8 +/- 8.0 for HVA, 58.2 +/- 18.5 for 5-HIAA and 14.2 +/- 5.0 for MHPG. The score of the DR scale was improved by 5 or less after the idebenone medication in most subjects. HVA and 5-HIAA increased markedly in the patients who showed a tendency of improvement of mental impairment as evaluated by the DR scale. The results suggested that idebenone would improve abnormalities in neurotransmitters of patients with cerebrovascular dementia, especially promoting serotonin turnover

Home | Order

Idebenone - the ultimate anti-aging drug.  (article)
Alzheimer's disease
Idebenone  in the treatment of Alzheimer's disease
Idebenone  efficacy of idebenone in the treatment of Alzheimer's disease
Idebenone  Nerve Growth Factor synthesis stimulators in Alzheimer's disease
Idebenone  in the treatment of dementia of the Alzheimer type
Idebenone  cognitive enhancement therapy for Alzheimer's disease

Friedreich's ataxia.
Idebenone  and reduced cardiac hypertrophy in Friedreich's ataxia.
enone  causes improvement in mitochondrial cardiomyopathy
Idebenone  cerebellar improvement in Friedreich's ataxia after 3 months
Idebenone   effect of idebenone on cardiomyopathy in Friedreich's ataxia
Idebenone  Friedreich's ataxia and frataxin
Idebenone   Frataxin: Its role in iron metabolism and Friedreich's Ataxia
Idebenone   mitochondrial dysfunction in Friedreich's ataxia
Idebenone   helps heart function in Friedreich's ataxia

Idebenone  improves cerebral mitochondrial oxidative metabolism in MELAS
Idebenone  in young patients with mitochondrial encephalomyopathy (MELAS)
Idebenone  therapy in Mitochondrial encephalomyopathy (MELAS)
Idebenone  and Mitochondrial encephalomyopathy (MELAS)
Idebenone  successful therapy with idebenone in Mitochondrial encephalomyopathy (MELAS)
Idebenone  improvement in mitochondrial cardiomyopathy following treatment with idebenone

Idebenone   effect of idebenone on cardiomyopathy in Friedreich's ataxia

Leber hereditary optic neuropathy (LHON)
Idebenone  does it shorten the time to visual recovery in Leber hereditary optic neuropathy?
Idebenone  improvement in a patient with Leber's hereditary optic neuropathy (LHON)

Idebenone  use in age-related cognitive disorders

Idebenone  protects hippocampal neurons against beta amyloid neurotoxicity

functions as a potent protective hepatocyte antioxidant

neuroprotective effects of idebenone can be attributed to its antioxidant ability

inhibition of brain mitochondrial swelling

suppression of cold ischemia/reperfusion injury of liver endothelium

ability to eliminate a nitroxide radical in the rat

Idebenone  interaction with respiratory complexes of heart mitochondria

Idebenone  effect on serotonin release and seroton receptors in rats

Idebenone  protects hepatic microsomes against damage in organ preservation solutions

protects against toxicity induced by low density lipoprotein

Idebenone  protects against disorders due to cerebral hypoxia or ischemia

Idebenone  protects against toxicity induced by low density lipoprotein

Idebenone  attenuates neuronal degeneration induced by excitotoxins

Idebenone  augments long-term potentiation in hippocampal slices in the guinea pig

effects on lipid peroxidation in erythrocytes of stroke-prone, hypertensive rats

Idebenone  brain distribution and its effect on local cerebral glucose utilization in rats

Idebenone  effects on acetylcholine levels in the brains of rats with cerebral ischemia

Idebenone  protective effect of idebenone against hypoxia in mice

Idebenone  improves learning and memory impairment induced in rats

Idebenone  effects of idebenone on neurological deficits in stroke-prone rats

  effects on memory induced impairment in rats

Idebenone  effects of idebenone on cerebral blood flow in rats with cerebral ischemia

inhibition of brain mitochondrial swelling by idebenone

inhibition of platelet aggregation by idebenone

Idebenone  effects of idebenone on monoamine metabolites of patients with dementia

effects of idebenone on metabolism of monoamines and cyclic AMP formation

  effects on impairment of radial maze learning in cerebral embolized rats

Idebenone  effect of idebenone on lipid peroxidation in rat brain homogenate

Idebenone  effects on muricidal behavior in rats with raphe lesions

Idebenone  inhibitory effect of idebenone on vascular lesions in hypertensive rats

Home | Order